Download the Protocol

CJC-1295 (with DAC)

CJC-1295 with DAC is a long-lasting version of a natural hormone signal that helps the body release growth hormone. It supports recovery, better sleep, and healthy tissue repair by extending the body’s natural hormone rhythm for several days after each dose.

Description

• CJC-1295 with DAC (Drug Affinity Complex) is a synthetic peptide analog of Growth Hormone-Releasing Hormone (GHRH).
• Engineered with a DAC extension that binds to serum albumin, extending its half-life significantly compared to standard GHRH analogs.
• Studied for its potential to increase pulsatile Growth Hormone (GH) and Insulin-like Growth Factor 1 (IGF-1) secretion.

How It Works

• Binds to GHRH receptors on pituitary somatotrophs, stimulating endogenous GH release.
• DAC modification allows prolonged circulation (up to ~7 days), leading to sustained GH/IGF-1 elevations.
• Supports recovery, muscle development, and metabolic regulation in experimental models.

Documented Effects

• Increases serum GH and IGF-1 for several days after a single injection in research studies.
• Enhances protein synthesis and lean tissue retention in animal models.
• May promote improved sleep quality and cellular repair signals.

Theoretical Effects

• Potential to improve recovery, energy, and fat metabolism via GH axis stimulation.
• Synergistic effects observed when combined with GHRPs (e.g., Ipamorelin or GHRP-6) in studies.
• Human therapeutic safety and efficacy not yet confirmed outside of controlled research.

Pharmacokinetics

• Half-life: approximately 6–8 days due to DAC modification.
• Time to peak concentration: about 12–24 hours after injection.
• Steady-state: reached within 3–4 weeks of consistent weekly use.

Duration of Effects

• Growth hormone stimulation lasts for up to 7 days per injection.
• Effects such as improved recovery and sleep may persist several days beyond dosing.
• Benefits taper gradually after discontinuation within 1–2 weeks.

Reconstitution

• Use only bacteriostatic water to reconstitute the lyophilized powder.
• Example vial: 5 mg of CJC-1295 (with DAC)
• Choose reconstitution volume based on dosing convenience:
  • 1 mL water → 5 mg/mL → 500 mcg per 10 units
  • 2 mL water → 2.5 mg/mL → 250 mcg per 10 units
• Swirl gently to dissolve; do not shake.
• Refrigerate reconstituted solution (2–8 °C). Use within ~30 days for best stability.

Injectable Dosage Overview (Research Use)

Typical Starting Dose

• Injectable (research use): 250–500 mcg subcutaneous (SC) once or twice weekly.
• Conservative start: 250 mcg per injection to evaluate tolerance.

Common Research Range

• Typical usage: 250–1000 mcg SC per injection, 1–2 times per week.
• Often combined with GHRPs for enhanced pulsatile GH release.

Maximum Reported Range

• Anecdotal ceiling: 2 mg per week total dose.
• Higher exposure offers no proven additional benefit and may desensitize GH receptors over time.

Standard Cycle Length

• Research cycles typically 8–12 weeks.
• Off-cycles of equal length are suggested to maintain receptor sensitivity.

Clinical Notes

• Administer subcutaneously in the abdomen or thigh once or twice weekly.
• No tapering required; hormone levels decline naturally after discontinuation.
• May be paired with GHRPs (Ipamorelin, GHRP-6) for synergistic GH pulses.
• Stable for about 30 days when refrigerated (2–8°C). Protect from light and heat. Avoid freezing.

Safety Notes (First-Time Use)

• Possible transient flushing, dizziness, or mild water retention post-injection.
• Monitor injection site reactions and discontinue if irritation persists.
• Research use only; not approved for therapeutic human use.